The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors

Approximately 121.5 million adults in the United States have cardiovascular disease; it is the leading cause of death in this country. The earlier patients begin to follow heart healthy lifestyles and modify risk factors, the greater their reduction in overall risk. In this activity, an expert lipidologist will review the most recent American College of Cardiology/American Heart Association guidelines on dyslipidemia, covering primary prevention as well as secondary prevention in patients with clinical atherosclerotic cardiovascular disease. He will also provide guidance regarding a patient-centered approach to the management of patients with dyslipidemia, including lifestyle management and when and how to use high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.
Douglas Jacoby, MD
Mary Knudtson, DNSc, NP, FAAN

Interactive Virtual Presentation

Approximately 121.5 million adults in the United States have cardiovascular disease; it is the leading cause of death in this country. The earlier patients begin to follow heart healthy lifestyles and modify risk factors, the greater their reduction in overall risk. In this activity, an expert lipidologist will review the most recent American College of Cardiology/American Heart Association guidelines on dyslipidemia, covering primary prevention as well as secondary prevention in patients with clinical atherosclerotic cardiovascular disease. He will also provide guidance regarding a patient-centered approach to the management of patients with dyslipidemia, including lifestyle management and when and how to use high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.

Douglas Jacoby, MD Mary Knudtson, DNSc, NP, FAAN Released: August 31, 2019
Provided by Boston University School of Medicine

Boston University School of Medicine
Continuing Medical Education
72 East Concord Street, A402
Boston, Massachusetts 02118

(617) 638-4605
(617) 638-4905 (Fax)
http://www.bu.edu/cme

This activity was developed from a series of programs cosupported by educational grants from
AbbVie
Boehringer Ingelheim Pharmaceuticals, Inc.
Genentech
Novartis Pharmaceuticals Corporation
Sanofi US
Regeneron Pharmaceuticals
Shire
Teva Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue